(Health-NewsWire.Net, May 27, 2017 ) Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include lump that can be felt through the skin on neck, difficulty swallowing, pain in neck and throat and swollen lymph nodes in neck. Predisposing factors include female, high levels of radiation and inherited genetic syndromes. Treatment includes surgery and thyroid hormone therapy.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Thyroid Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Thyroid Cancer (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Thyroid Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Thyroid Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, and Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 29, 21, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 5 molecules, respectively.
Thyroid Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/thyroid-cancer-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Thyroid Cancer (Oncology) . - The pipeline guide reviews pipeline therapeutics for Thyroid Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Thyroid Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Thyroid Cancer (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Thyroid Cancer (Oncology)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001709419/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Thyroid Cancer (Oncology) . - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Thyroid Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
AbbVie Inc Advenchen Laboratories LLC AstraZeneca Plc Bayer AG BeiGene Ltd Biovista Inc Blueprint Medicines Corp Boehringer Ingelheim GmbH Celgene Corp Celldex Therapeutics Inc Cytori Therapeutics Inc Daiichi Sankyo Company Ltd Ecrins Therapeutics SAS Eisai Co Ltd Ensol Biosciences Inc F. Hoffmann-La Roche Ltd Genelux Corp Genmab A/S GlaxoSmithKline Plc Gradalis Inc Hutchison MediPharma Ltd Ignyta Inc Immune Pharmaceuticals Inc Immunomedics Inc Johnson & Johnson Loxo Oncology Inc MacroGenics Inc MaxiVAX SA Merck & Co Inc Merck KGaA Millennium Pharmaceuticals Inc Nerviano Medical Sciences Srl Novartis AG Ono Pharmaceutical Co Ltd Pfizer Inc Plexxikon Inc Rodos BioTarget GmbH Savoy Pharmaceuticals Inc Synactix Pharmaceuticals Inc Tarveda Therapeutics Inc Vaccinex Inc Vascular Biogenics Ltd
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001709419/discount
List of Tables
Number of Products under Development for Thyroid Cancer, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Thyroid Cancer - Pipeline by AbbVie Inc, H1 2017 Thyroid Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017 Thyroid Cancer - Pipeline by AstraZeneca Plc, H1 2017 Thyroid Cancer - Pipeline by Bayer AG, H1 2017 Thyroid Cancer - Pipeline by BeiGene Ltd, H1 2017 Thyroid Cancer - Pipeline by Biovista Inc, H1 2017 Thyroid Cancer - Pipeline by Blueprint Medicines Corp, H1 2017 Thyroid Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017 Thyroid Cancer - Pipeline by Celgene Corp, H1 2017 Thyroid Cancer - Pipeline by Celldex Therapeutics Inc, H1 2017 Thyroid Cancer - Pipeline by Cytori Therapeutics Inc, H1 2017 Thyroid Cancer - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 Thyroid Cancer - Pipeline by Ecrins Therapeutics SAS, H1 2017 Thyroid Cancer - Pipeline by Eisai Co Ltd, H1 2017 Thyroid Cancer - Pipeline by Ensol Biosciences Inc, H1 2017 Thyroid Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Thyroid Cancer - Pipeline by Genelux Corp, H1 2017 Thyroid Cancer - Pipeline by Genmab A/S, H1 2017 Thyroid Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017 Thyroid Cancer - Pipeline by Gradalis Inc, H1 2017 Thyroid Cancer - Pipeline by Hutchison MediPharma Ltd, H1 2017 Thyroid Cancer - Pipeline by Ignyta Inc, H1 2017 Thyroid Cancer - Pipeline by Immune Pharmaceuticals Inc, H1 2017 Thyroid Cancer - Pipeline by Immunomedics Inc, H1 2017 Thyroid Cancer - Pipeline by Johnson & Johnson, H1 2017 Thyroid Cancer - Pipeline by Loxo Oncology Inc, H1 2017 Thyroid Cancer - Pipeline by MacroGenics Inc, H1 2017 Thyroid Cancer - Pipeline by MaxiVAX SA, H1 2017 Thyroid Cancer - Pipeline by Merck & Co Inc, H1 2017 Thyroid Cancer - Pipeline by Merck KGaA, H1 2017 Thyroid Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017 Thyroid Cancer - Pipeline by Nerviano Medical Sciences Srl, H1 2017 Thyroid Cancer - Pipeline by Novartis AG, H1 2017 Thyroid Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 Thyroid Cancer - Pipeline by Pfizer Inc, H1 2017 Thyroid Cancer - Pipeline by Plexxikon Inc, H1 2017 Thyroid Cancer - Pipeline by Rodos BioTarget GmbH, H1 2017 Thyroid Cancer - Pipeline by Savoy Pharmaceuticals Inc, H1 2017 Thyroid Cancer - Pipeline by Synactix Pharmaceuticals Inc, H1 2017 Thyroid Cancer - Pipeline by Tarveda Therapeutics Inc, H1 2017 Thyroid Cancer - Pipeline by Vaccinex Inc, H1 2017 Thyroid Cancer - Pipeline by Vascular Biogenics Ltd, H1 2017 Thyroid Cancer - Dormant Projects, H1 2017 Thyroid Cancer - Dormant Projects, H1 2017 (Contd...1) , H1 2017 Thyroid Cancer - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001709419/buy/2000
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|